Company Outline

a bioventure company with academic origins

Management President & CEO – Satoru Ito
Shareholders Founder & academic (38.1%), Corporate (2 companies, 7.1%),
Venture capital (3 companies, 17.1%), individuals (23, 37.7%)
Paid-in-capital \90M
Capital reserve \250M


Corporate Philosophy

Creation of innovative medicines

Targeting diseases with unmet medical need especially inflammatory diseases and cancer

promotion of collaboration with academia

Building a collaborative system aimed at global development



02-Apr-2012 IDAC Theranostidas,Inc. is established in Hongo,Bunkyo-ku,Tokyo.
Its capital is increased to 10million yen.
08-Jun-2012 Capital is increased to 20million yen.
06-Aug-2012 Acquired of exclusive license of humanized anti-human CD4 antibody from Kyowa Hakko Kirin Co., Ltd.
05-Sep-2012 IDAC open a research facility in Tsurumi-ku, Yokohama-shi.
25-Mar-2013 Capital is increased to 57million yen.
30-Aug-2013 Capital is increased to 116million yen.
01-Sep-2013 Signed an exclusive licensing contract for humanized anti-human CD4 antibody from Tokyo Univ.
07-Nov-2014 Capital is increased to 394.5million yen.
16-May-2016 Signed an exclusive licensing option contract for humanized anti-human CD4 antibody (IT 1208) under development with Ono Pharmaceutical Co., Ltd.
29-Sep-2017 Capital is increased to 594.9million yen.
30-Nov-2017 Capital reduction to 250million yen.
31-Aug-2018 Capital reduction to 90million yen.



Machida Heights Ⅰ 1-3, Haramachida 1-13-1, Machida, Tokyo, 194-0013 Japan